ロード中...
Update on the clinical utility of sildenafil in the treatment of pulmonary arterial hypertension
Sildenafil is an orally administered phosphodiesterase type 5 inhibitor that is approved for the treatment of pulmonary arterial hypertension (PAH). The hemodynamic effects of sildenafil are mitigated primarily via potentiating the effects of endogenous nitric oxide, leading to smooth muscle cell re...
保存先:
| 主要な著者: | , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Dove Medical Press
2010
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2880338/ https://ncbi.nlm.nih.gov/pubmed/20531962 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|